2023/03/28 更新

写真a

ナリタ コウタロウ
成田 幸太郎
NARITA Kotaro
所属
医学部附属病院 病院戦略室 病院助教
職名
病院助教

学位 2

  1. 博士(医学) ( 2023年2月   名古屋大学 ) 

  2. 学士(医学) ( 2010年3月   名古屋大学 ) 

経歴 1

  1. 厚生労働省   健康局がん・疾病対策課   課長補佐

    2021年4月 - 2022年4月

 

論文 10

  1. Human leukocyte antigen 7/8-matched unrelated bone marrow transplantation using anti-thymocyte globulin in children 査読有り

    Hamada Motoharu, Muramatsu Hideki, Torii Yuka, Suzuki Kyogo, Narita Atsushi, Yoshida Taro, Imaya Masayuki, Yamamori Ayako, Wakamatsu Manabu, Miwata Shunsuke, Narita Kotaro, Kataoka Shinsuke, Kawashima Nozomu, Taniguchi Rieko, Nishikawa Eri, Nishio Nobuhiro, Ito Yoshinori, Kojima Seiji, Takahashi Yoshiyuki

    INTERNATIONAL JOURNAL OF HEMATOLOGY     2023年3月

     詳細を見る

    記述言語:英語   出版者・発行元:International Journal of Hematology  

    Human leukocyte antigen (HLA) mismatched unrelated donor transplantation is associated with an increased risk of graft-versus-host disease, graft failure, and infection, which increases post-transplant morbidity and mortality. In this single-center retrospective study, outcomes were evaluated in 30 consecutive children who underwent bone marrow transplantation (BMT) from HLA 1 allele-mismatched (HLA 7/8-matched) unrelated donors with rabbit anti-thymocyte globulin (rATG) as graft-versus-host disease (GVHD) prophylaxis. The 3-year overall survival (OS), event-free survival (EFS), and GVHD-relapse-free survival rates were 91.7% (95% CI 70.5%–91.9%), 88.3% (95% CI 67.5%–96.1%), and 73.9% (95% CI 52.4%–86.8%), respectively. Grade II–IV and III–IV acute GVHD occurred in 10 (33%) and 2 (7.0%) patients, respectively. The 3-year cumulative incidence of chronic GVHD was 7.8%. No fatal viral infections occurred. The study results show the feasibility of HLA 7/8-matched unrelated BMT with ATG to achieve favorable outcomes and acceptable GVHD, especially for patients who lack a fully matched donor.

    DOI: 10.1007/s12185-023-03571-5

    Web of Science

    Scopus

    PubMed

  2. Germline and somatic RUNX1 variants in a pediatric bone marrow failure cohort 査読有り

    Yamamori Ayako, Hamada Motoharu, Muramatsu Hideki, Wakamatsu Manabu, Hama Asahito, Narita Atsushi, Tsumura Yusuke, Yoshida Taro, Doi Takehiko, Terada Kazuki, Higa Takeshi, Yamamoto Nobuyuki, Miura Hiroki, Shiota Mitsutaka, Watanabe Kenichiro, Yoshida Nao, Maemura Ryo, Imaya Masayuki, Miwata Shunsuke, Narita Kotaro, Kataoka Shinsuke, Taniguchi Rieko, Suzuki Kyogo, Kawashima Nozomu, Nishio Nobuhiro, Iwafuchi Hideto, Ito Masafumi, Kojima Seiji, Okuno Yusuke, Takahashi Yoshiyuki

    AMERICAN JOURNAL OF HEMATOLOGY     2023年2月

     詳細を見る

    記述言語:英語   出版者・発行元:American Journal of Hematology  

    DOI: 10.1002/ajh.26874

    Web of Science

    Scopus

    PubMed

  3. TREATMENT-RELATED TOXICITY OF ANTI-GD2 ANTIBODY IMMUNOTHERAPY AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN HIGH-RISK NEUROBLASTOMA PATIENTS 査読有り

    Kataoka Shinsuke, Yamamori Ayako, Imaya Masayuki, Wakamatsu Manabu, Narita Kotaro, Taniguchi Rieko, Narita Atsushi, Muramatsu Hideki, Nishio Nobuhiro, Takahashi Yoshiyuki

    PEDIATRIC BLOOD & CANCER   69 巻   2022年11月

     詳細を見る

  4. LI-FRAUMENI SYNDROME DIAGNOSED BY ONCOGENE PANEL TESTING FOR RHABDOMYOSARCOMA 査読有り

    Taniguchi Rieko, Narita Atsushi, Muramatsu Hideki, Yamashita Daiki, Sajiki Daichi, Imaya Masayuki, Wakamatsu Manabu, Narita Kotaro, Nishio Nobuhiro, Takahashi Yoshiyuki

    PEDIATRIC BLOOD & CANCER   69 巻   2022年11月

     詳細を見る

  5. RISK FACTORS FOR BLOOD STREAM INFECTIONS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN CHILDREN 査読有り

    Sajiki Daichi, Muramatsu Hideki, Wakamatsu Manabu, Narita Kotaro, Kataoka Shinsuke, Taniguchi Rieko, Narita Atsushi, Nishio Nobuhiro, Takahashi Yoshiyuki

    PEDIATRIC BLOOD & CANCER   69 巻   2022年11月

     詳細を見る

  6. THE DISAPPEARANCE OF MINIMAL RESIDUAL DISEASE IN BONE MARROW DEMONSTRATES GRAFT VERSUS NEUROBLASTOMA EFFECT AFTER KIR-LIGAND MISMATCHED ALLOGENEIC CBT 査読有り

    Alahmadi Rowaida, Nishio Nobuhiro, Wakamatsu Manabu, Kataoka Shinsuke, Narita Kotaro, Taniguchi Rieko, Narita Atsushi, Muramatsu Hideki, Takahashi Yoshiyuki

    PEDIATRIC BLOOD & CANCER   69 巻   2022年11月

     詳細を見る

  7. Whole-exome analysis of 177 pediatric patients with undiagnosed diseases 査読有り 国際誌

    Narita Kotaro, Muramatsu Hideki, Narumi Satoshi, Nakamura Yuji, Okuno Yusuke, Suzuki Kyogo, Hamada Motoharu, Yamaguchi Naoya, Suzuki Atsushi, Nishio Yosuke, Shiraki Anna, Yamamori Ayako, Tsumura Yusuke, Sawamura Fumi, Kawaguchi Masahiro, Wakamatsu Manabu, Kataoka Shinsuke, Kato Kohji, Asada Hideyuki, Kubota Tetsuo, Muramatsu Yukako, Kidokoro Hiroyuki, Natsume Jun, Mizuno Seiji, Nakata Tomohiko, Inagaki Hidehito, Ishihara Naoko, Yonekawa Takahiro, Okumura Akihisa, Ogi Tomoo, Kojima Seiji, Kaname Tadashi, Hasegawa Tomonobu, Saitoh Shinji, Takahashi Yoshiyuki

    SCIENTIFIC REPORTS   12 巻 ( 1 ) 頁: 14589   2022年8月

     詳細を見る

    担当区分:筆頭著者   記述言語:英語   出版者・発行元:Scientific Reports  

    Recently, whole-exome sequencing (WES) has been used for genetic diagnoses of patients who remain otherwise undiagnosed. WES was performed in 177 Japanese patients with undiagnosed conditions who were referred to the Tokai regional branch of the Initiative on Rare and Undiagnosed Diseases (IRUD) (TOKAI-IRUD). This study included only patients who had not previously received genome-wide testing. Review meetings with specialists in various medical fields were held to evaluate the genetic diagnosis in each case, which was based on the guidelines of the American College of Medical Genetics and Genomics. WES identified diagnostic single-nucleotide variants in 66 patients and copy number variants (CNVs) in 11 patients. Additionally, a patient was diagnosed with Angelman syndrome with a complex clinical phenotype upon detection of a paternally derived uniparental disomy (UPD) [upd(15)pat] wherein the patient carried a homozygous DUOX2 p.E520D variant in the UPD region. Functional analysis confirmed that this DUOX2 variant was a loss-of-function missense substitution and the primary cause of congenital hypothyroidism. A significantly higher proportion of genetic diagnoses was achieved compared to previous reports (44%, 78/177 vs. 24–35%, respectively), probably due to detailed discussions and the higher rate of CNV detection.

    DOI: 10.1038/s41598-022-14161-6

    Web of Science

    Scopus

    PubMed

  8. Combination chemotherapy consisting of irinotecan, etoposide, and carboplatin for refractory or relapsed neuroblastoma 査読有り

    Imaya Masayuki, Muramatsu Hideki, Narita Atsushi, Yamamori Ayako, Wakamatsu Manabu, Yoshida Taro, Miwata Shunsuke, Narita Kotaro, Ichikawa Daisuke, Hamada Motoharu, Nishikawa Eri, Kawashima Nozomu, Nishio Nobuhiro, Kojima Seiji, Takahashi Yoshiyuki

    CANCER MEDICINE   11 巻 ( 9 ) 頁: 1956 - 1964   2022年5月

     詳細を見る

    記述言語:英語   出版者・発行元:Cancer Medicine  

    Background: Patients with primary refractory and relapsed neuroblastoma have a poor prognosis since safe and effective chemotherapies for these patients are currently limited. The development of new chemotherapy regimens for these patients is imperative to improve survival outcomes. Methods: We retrospectively analyzed 40 patients with refractory (n = 36) or relapsed (n = 4) neuroblastoma who received irinotecan, etoposide, and carboplatin (IREC) as a second-line treatment. We evaluated their therapeutic response and the toxicity of IREC. We also assessed the impact of UGT1A1 gene polymorphisms, which are involved in irinotecan metabolism, on outcomes and toxicity. Results: A total of 112 cycles of IREC were administered to 40 patients with a median of 2 cycles per patient (range, 1–9). Six (15%) patients (UGT1A1 wild-type [n = 2] and heterozygous [n = 4]) showed objective responses, including partial response (n = 1), tumor shrinkage (n = 4), and improved findings on their MIBG scan (n = 1). Grade 4 neutropenia, grade 4 leukopenia, and grades 3–4 gastrointestinal toxicity were observed in 110 (98%), 88 (79%), and 3 (3%) cycles, respectively. There was no IREC-related mortality. Patients with UGT1A1 polymorphisms showed a higher frequency of grade 4 leukopenia, but these patients did not have increased treatment-related mortality or non-hematologic toxicity. Conclusions: IREC showed an objective response rate of 15% including 1 case with partial response. IREC was well tolerated regardless of UGT1A1 genotype. This study suggests that IREC is a promising second-line chemotherapy for refractory or relapsed neuroblastoma.

    DOI: 10.1002/cam4.4529

    Web of Science

    Scopus

    PubMed

  9. Short Report Nosocomial infection with rotavirus vaccine strain in paediatric patients with immunodeficiency 査読有り

    Miura H., Taniguchi K., Narita K., Kawamura Y., Kozawa K., Muramatsu H., Takahashi Y., Ihira M., Yoshikawa T.

    JOURNAL OF HOSPITAL INFECTION   121 巻   頁: 9 - 13   2022年3月

     詳細を見る

    記述言語:英語   出版者・発行元:Journal of Hospital Infection  

    In infants with immunodeficiency, rotavirus (RV) vaccines can be continuously excreted in stool. We analysed nosocomial infection with RV vaccine strain in immunodeficient paediatric patients. RV1 RNAs were detected in stool and serum samples from case A, who was vaccinated with RV1, and case B, who was not. PAGE analysis of serial stool samples of case A revealed several rearrangements of the RV genome. In case B, the only band pattern detected was the same as a rearrangement detected in case A at the same time. In summary, RV vaccination of infants with immunodeficiency poses a risk of nosocomial infections.

    DOI: 10.1016/j.jhin.2021.12.009

    Web of Science

    Scopus

    PubMed

  10. Clinical Impact of Melphalan Pharmacokinetics on Transplantation Outcomes in Children Undergoing Hematopoietic Stem Cell Transplantation 査読有り

    Maemura Ryo, Wakamatsu Manabu, Matsumoto Kana, Sakaguchi Hirotoshi, Yoshida Nao, Hama Asahito, Yoshida Taro, Miwata Shunsuke, Kitazawa Hironobu, Narita Kotaro, Kataoka Shinsuke, Ichikawa Daisuke, Hamada Motoharu, Taniguchi Rieko, Suzuki Kyogo, Kawashima Nozomu, Nishikawa Eri, Narita Atsushi, Okuno Yusuke, Nishio Nobuhiro, Kato Koji, Kojima Seiji, Morita Kunihiko, Muramatsu Hideki, Takahashi Yoshiyuki

    CELL TRANSPLANTATION   31 巻   頁: 9636897221143364   2022年

     詳細を見る

    記述言語:英語   出版者・発行元:Cell Transplantation  

    Melphalan is widely used for hematopoietic stem cell transplantation (HSCT) conditioning. However, the relationship between its pharmacokinetic (PK) and transplantation outcomes in children has not been thoroughly investigated. We prospectively analyzed the relationship between melphalan area under the curve (AUC) and transplantation outcome and examined the development of a predictive model for melphalan clearance in children. This study included 43 children aged 0 to 19 years who underwent HSCT following a melphalan-based conditioning regimen from 2017 to 2021. In univariable analysis, high-melphalan AUC resulted in a significantly lower cumulative incidence of acute graft-versus-host disease and a higher cumulative incidence of thrombotic microangiopathy, although no significant difference was observed in survival. Regression analysis of a randomly selected derivation cohort (n = 21) revealed the following covariate PK model: predicted melphalan clearance (mL/min) = 6.47 × 24-h urinary creatinine excretion rate (CER, g/day) × 24-h creatinine clearance rate (CCR, mL/min) + 92.8. In the validation cohort (n = 22), the measured melphalan clearance values were significantly correlated with those calculated based on the prediction equation (R2 = 0.663). These results indicate that melphalan exposure may be optimized by adjusting the melphalan dose according to CER and CCR.

    DOI: 10.1177/09636897221143364

    Web of Science

    Scopus

    PubMed

▼全件表示